[ODP7C] c. Others

[ODP-215] Development of the photo-antibacterial targeting therapy

○Kazuhide Sato^1,2,3,4, Hirotoshi Yasui³, Kazuomi Takahashi³, Shunichi Taki³, Tomohiro Akashi⁵, Yoshiyuki Nakagawa⁵ (¹Nagoya Univ. Institute for Advanced Research, ²Nagoya Univ. Institute for Advanced Research, Advanced Analytical and Diagnostic Imaging Center (AADIC) / Medical Engineering Unit (MEU), ³Respiratory Medicine, Nagoya Univ. Grad. Sch. Medicine, ⁴Nagoya Univ. Institute of Nano-Life-Systems, Institutes of Innovation for Future Society, ⁵Div. OMICS analysis, Nagoya Univ. Grad. Sch. Medicine)

Purpose: In recent years, resistant bacteria are becoming more and more difficult to treat in clinical practice, and it is desirable to develop a treatment method that is different from conventional concepts. To address this issue, we are developing targeted photo-antibacterial targeting therapy (PAT2) using near-infrared light.
Methods: Chickens were immunized with Candida albicans antigen and anti-Candida albicans IgY (CA-IgY) was produced. Then, IgY was conjugated with IR700 to prepare CA-IgY-IR700. Binding of human skin cancer cells, A431 and C.albicans related strains, to CA-IgY-IR700 was assessed. The effect of PAT2 in vitro was examined with microscopy. We also examined the effects of PAT2 in vivo using a mouse skin ulcer infection model.
Results: CA-IgY-IR700 did not bind to human cells but was widely bound to the Candida family. The effect of PAT2 in vitro was increased in a dose-dependent manner for NIR-light. PAT2 was found to have a rapid cell death effect; in vivo PAT2 was found to have a marked infection ulcer healing effect and was also found to be an appropriate targeted treatment without causing extra inflammation from treatment.
Conclusions: PAT2 with CA-IgY-IR700 was considered a highly selective and promising antimicrobial therapy.